NITD 609 clinical trials
Also written KAE609 and Cipargamin.
How each study uses NITD 609 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the NITD 609 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test NITD 609.
- Feb 2027Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)Phase 2 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses NITD 609 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)RecruitingPhase 2Novartis PharmaceuticalsNCT07811908Written as KAE609
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum MalariaRecruitingPhase 2Novartis PharmaceuticalsNCT05750628Written as KAE609 (Cipargamin)
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)CompletedPhase 2Novartis PharmaceuticalsNCT07235033Written as KAE609
- To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum MalariaCompletedPhase 2Novartis PharmaceuticalsNCT04675931Written as Cipargamin
- Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy SubjectsCompletedPhase 1Novartis PharmaceuticalsNCT04321252Written as KAE609
- Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.CompletedPhase 2Novartis PharmaceuticalsNCT03334747Written as KAE609
- Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to MosquitosTerminatedPhase 1Novartis PharmaceuticalsNCT02543086Written as KAE609
- A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum MonoinfectionCompletedPhase 2Novartis PharmaceuticalsNCT01836458Written as KAE609
- A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infectionCompletedPhase 2Novartis PharmaceuticalsNCT01860989Written as KAE609
- Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infectionCompletedPhase 2Novartis PharmaceuticalsNCT01524341Written as KAE609
Given beside what is tested · 1 — NITD 609 is usual care or a partner of the new treatment
Codes
What other systems call NITD 609 · ClinicalTrials.gg INT005708
- MeSH (NLM) C552304NITD 609One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C552304 | NITD 609 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.